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Abstract: Doxorubicin (DOX) is an anthracycline widely used in cancer therapy and in particular in
breast cancer treatment. The treatment with DOX appears successful, but it is limited by a severe
cardiotoxicity. This work evaluated the in vitro and in vivo anticancer effect of a new formulation of
β-cyclodextrin nanosponges containing DOX (BNS-DOX). The BNS-DOX effectiveness was evaluated
in human and mouse breast cancer cell lines in vitro in terms of effect on cell growth, cell cycle
distribution, and apoptosis induction; and in vivo in BALB-neuT mice developing spontaneous breast
cancer in terms of biodistribution, cancer growth inhibition, and heart toxicity. BNS-DOX significantly
inhibited cancer cell proliferation, through the induction of apoptosis, with higher efficiency than free
DOX. The breast cancer growth in BALB-neuT mice was inhibited by 60% by a BNS-DOX dose five
times lower than the DOX therapeutic dose, with substantial reduction of tumor neoangiogenesis
and lymphangiogenesis. Biodistribution after BNS-DOX treatment revealed a high accumulation of
DOX in the tumor site and a low accumulation in the hearts of mice. Results indicated that use of
BNS may be an efficient strategy to deliver DOX in the treatment of breast cancer, since it improves
the anti-cancer effectiveness and reduces cardiotoxicity.
Keywords: β-cyclodextrin nanosponges; doxorubicin; breast cancer; BALB-neuT mice; EPR effect
1. Introduction
Doxorubicin (DOX) is one of the most effective anticancer drugs used against solid tumors of
diverse origins and in particular against breast cancer. However, its use is associated with severe adverse
effects including cardiotoxicity, myelosuppression and palmar plantar erythrodysenthesia, which
impose a narrow therapeutic dose limiting DOX effectiveness [1]. Moreover, cancer cells frequently
become resistant to DOX treatment and some conditions of the tumor microenvironment-such as
hypoxia, acidity, defective vasculature, and lymphatic vessels-limit the DOX anticancer effectiveness [2].
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Hence, there is necessity for an effective approach that limits DOX side effects by reducing DOX
doses and modifying its bio-distribution to favor its concentration into the tumor site. To this aim, we
evaluated the possibility of incorporating DOX into nanoparticles capable of favoring accumulation of
the drug into the tumor site. In recent years, the development of nano-delivery systems for anticancer
agents, with dimensions of less than 1000 nm have been found to be acceptable for intravenous
administration, and have improved the therapeutic effectiveness of several compounds. Compared to
conventional carriers, they report several advantages, such as capacity to solubilize hydrophobic drugs,
reduction of total drug dose, and prevention of side effects [3]. When infused in the bloodstream,
nanoparticles can accumulate in tumors owing to the enhanced permeability and retention (EPR) effect
since the immature vasculature of tumors display fenestrations smaller than 200 nm, allowing for
extravasation and entrapment of nanoparticles from the blood into the tumor tissue [4]. Recent studies
showed that DOX and mitomycin C, co-loaded in polymer–lipid hybrid nanoparticles, inhibited the
growth of sensitive and multidrug resistant human mammary tumor xenografts [2].
Many cyclodextrin (CD) derivatives have been proposed for drug delivery, and they have been
shown to improve bioavailability, aqueous solubility, and stability of hosted drugs [5–8]. β-cyclodextrin
nanosponges (BNS) are hyper-cross-linked polymers with CD units as the building blocks of the system
and are a biocompatible and suitable nanosystem to carry drugs [9–11]. Different anticancer drugs-such
as paclitaxel, camptothecin, and tamoxifen-have been efficiently incorporated in nanosponges, showing
an improved antitumor effect [12]. In this study, DOX was loaded in β-cyclodextrin based nanosponges
(BNS-DOX), and the effect of DOX and BNS-DOX was compared in vitro in human and mouse breast
cancer cell lines, either sensitive or resistant to DOX, and in vivo in the growth of spontaneous
mammary cancer in BALB-neuT mice, which mimics some of the most critical features of the human
disease and represents a real model of human epidermal growth factor receptor 2 (HER2) positive
breast cancer [13]. Results indicated that use of BNS may be an efficient strategy to deliver DOX in the
treatment of breast cancer, since it improves the anti-cancer efficacy and reduces cardiotoxicity.
2. Results
The in vitro and in vivo results are listed below. Table 1 reports the physico-chemical characteristics
of blank BNS and BNS loaded with DOX. BNS nanoformulations with an average diameter of about
300 nm and negative surface charge were obtained. Both the BNS nanoformulations displayed similar
sizes. Doxorubicin was incorporated in the nanosponge nanostructure in a good extent. Indeed,
the loading capacity and encapsulation efficiency of BNS-DOX were 16.4% and 98.5%, respectively.
Notably, the drug loading did not affect the physico-chemical parameters of BNS and the physical
stability of the nanosuspensions. The physical stability of BNS-DOX stored at 4 ◦C was confirmed up
to 1 month.
Table 1. Physico-chemical characteristics of blank and doxorubicin (DOX)-loaded β-cyclodextrin
nanosponges (BNS).
Formulation Average Diameter ± SD(nm) Polydispersity Index
Zeta Potential ± SD
(mV)
Blank BNS 302.5 ± 4.6 0.20 ± 0.01 −35.2 ± 2.7
BNS-DOX 310.4 ± 5.7 0.21 ± 0.01 −29.8 ± 1.3
The spherical morphology of BNS-DOX and their nanometric sizes were shown by Transmission
electron microscopy (TEM) analysis (Figure 1A).
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Figure 1. Characterization of β-cyclodextrin nanosponges containing doxorubicin (BNS-DOX). (A) 
Transmission electron microscopy image of BNS-DOX (scale bar 150 nm). (B) In vitro release kinetics 
of DOX from BNS-DOX at the two different pH levels (5.5 and 7.4). (C) In vitro release kinetics of 
DOX from BNS-DOX in rat plasma at 37 °C. 
DOX was released from BNS-DOX with a prolonged release kinetics, without initial burst effect 
(Figure 1B). This in vitro release profile confirmed the DOX incorporation in BNS polymeric matrix. 
The percentage of DOX released was higher at acidic pH values. Indeed, it increased about 2.5 fold 
at pH 5.5 compared to that at pH 7.4 (Figure 1B). The slow and prolonged in vitro release profile of 
DOX from BNS-DOX was observed also in plasma and it was comparable to that of the one obtained 
in phosphate buffered saline (PBS) at pH 7.4 (Figure 1C). After 24 h, the percentage of DOX released 
from the BNS was 10.5% and 13% in plasma and in buffer (pH 7.4), respectively. 
No changes in the BNS physico-chemical parameters and no aggregation phenomena were 
observed after incubation in plasma at 37 °C for 24 h, confirming the BNS-DOX stability. 
In order to determine the BNS-DOX effect in tumor cell growth, (3-(4,5-Dimethylthiazol-2-yl)-
2,5diphenyltetrazolium bromide (MTT) analysis was performed in breast tumor cells lines, which were 
human MDA-MB231 and MCF-7 cells (both DOX-sensitive), and mouse 4T1 (DOX-sensitive) and 
EMT6/AR10r (DOX-resistant) cells. MDA-MB231, 4T1, and EMT6/AR10r were chosen as models of 
triple negative tumors (TNBC)-i.e., negative for estrogen receptor (ER), progesterone receptor (PR), 
and HER2-while MCF-7 was chosen as a model of ER/PR positive tumors. 
To assess the effect on cell viability, cells were cultured in the presence and absence of titrated 
concentrations (10−5–10−9 M) of DOX or BNS-DOX and the MTT assay was performed after 72 h. 
Results showed that BNS-DOX inhibited cell viability in a concentration-dependent manner in all cell 
lines with higher efficacy than DOX (Figure 2). 
Figure 1. Characterization of β-cyclodextrin anosponges containi g doxorubicin (BNS-DOX). (A)
Transmission electron microsc py image of BNS-DOX (scale bar 150 nm). (B) In vitro release kinetics of
DOX from BNS-DOX at the two different pH levels (5.5 and 7.4). (C) In vitro release kinetics of DOX
from BNS-DOX in rat plasma at 37 ◦C.
DOX was rel ased from BNS-DOX with a prol nged rel ase kinetics, without in tial burst effect
(Figure 1B). This in vitro rel ase profile confirmed the DOX incorporation in BNS polymeric matrix.
The percentage of DOX released was hig er at acidic pH values. Indee , it increased about 2.5 fold at
pH 5.5 compared to that at pH 7.4 (Figure 1B). The slow and prolonged i vitro release profil of DOX
from BNS-DOX was observed also in plasma nd it was comparable to that of the one obtained in
phos ate buffered saline (PBS) at pH 7.4 (Figure 1C). After 24 h, the percentage of DOX released from
the BNS was 10.5% and 13% in plasma and in buffer (pH 7.4), respectiv ly.
No changes in the BNS physico-chemical par met rs and no aggregation phenomena wer
observed after incubation in plasma t 37 ◦C for 24 h, confirming the BNS-DOX stability.
In order to determine the BNS-DOX effect in t , (3-(4,5-Dimethylthiazol-
2-yl)-2,5diphenyltetrazoliu bromide (MTT) analysis was performed in breast tumor cells lines, which
were human MDA-MB231 and MCF-7 cells (both DOX-sensitive), se 4T1 (DOX-sensit ve) and
EMT6/AR10r (DOX-resi tant) cells. MDA-MB231, 4T1, and EMT6/AR10r wer chosen as models of
triple negative tumors (TNBC)-i.e , negative for estrogen receptor (ER), progesterone receptor (PR),
and HER2-while MCF-7 was chosen as a model of ER/PR positive tumors.
To asse s the ffect on cell viability, cells wer cultured in the pres nce and absence of titrated
concentrations (10−5–10−9 ) of DOX or BNS-DOX and the MT as ay was performed after 72 h.
Results showed that BNS-DOX inhib ted cell viability in a concentration-dependent manner in all cell
lines with igher effica y than DOX (Figure 2).
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Figure 2. Percentage of cell survival following DOX and BNS-DOX treatment. (A,B) MDA-MB231 and 
MCF-7 human breast cancer cell lines and (C,D) 4T1 and EMR6/AR10r mouse breast cancer cell lines 
were treated with increasing concentrations of the drugs for 72 h. Results are expressed as % of 
viability inhibition of control shown as mean ± SEM (n = 5). Eight replicate wells were used to 
determine each data point, and five different experiments were performed. * p < 0.05, ** p < 0.01, 
significantly different from the same concentration of DOX. 
In particular, EMT6/AR10r cells were quite resistant to both drug formulations and only the 
highest dose of BNS-DOX (10−5 M) substantially inhibited the cell growth. The empty BNS did not 
show any level of toxicity, even at high concentrations. Table 2 reports the half maximal inhibitory 
concentration (IC50) obtained from these experiments and shows that BNS-DOX displays lower IC50 
than DOX in all cell lines. 
Table 2. Half maximal inhibitory concentration (IC50) of BNS-DOX and DOX. 
Cell Line IC50 BNS-DOX IC50 DOX p-Value 
MDA-MB231 1.6 ± 0.2 × 10
−7
 5 ± 0.2 × 10
−7
 0.001 
4T1 2.8 ± 0.2 × 10
−8
 8.64 ± 0.8 × 10
−8
 0.0021 
EMT6/AR10r 5.3 ± 0.67 × 10
−6
 29 ± 0.9 × 10
−5
 0.0045 
MCF-7 1.5 ± 0.5 × 10
−8
 15 ± 0.9 × 10
−7
 0.001 
Two-tailed p-value has been determined with unpaired t-test with Welch correction. 
Results show that the inhibitory effect was exerted by BNS-DOX at a concentration always lower 
(3–10 times lower) than free DOX. Since a main limitation of DOX is its cardiotoxicity, we performed 
the same experiments on rat cardiomyocyte H9c2 cells, but results showed that BNS-DOX and DOX 
did not display a substantial difference in inhibiting cell viability of these cells. 
In order to assess whether the effects on the cell viability are related to inhibition of cell cycle 
progression, a cell cycle analysis was performed after 72 h of culture in the presence and absence of 
titrated amounts of DOX or BNS-DOX (Figure 3). 
Figure 2. Percentage of cell survival following DOX and BNS-DOX treatment. (A,B) MDA-MB231 and
MCF-7 human breast cancer cell lines and (C,D) 4T1 and EMR6/AR10r mouse breast cancer cell lines
were treated with increasing concentrations of the drugs for 72 h. Results are expressed as % of viability
inhibition of control shown as mean ± SEM (n = 5). Eight replicate wells were used to determine each
data point, and five different experiments were performed. * p < 0.05, ** p < 0.01, significantly different
from the same concentration of DOX.
I rti l r, / r ll r it r i t t t t r f r l ti l t
i t f - (10− ) s stantially i hibited t e ll r t . t i t
l l f t i it , t i c tr ti . l r rt t lf i l i i it r
tr ti (I 50) obtaine fr t ri t t t - is la s lo er IC50
t i ll ll li .
able 2. alf axi al inhibitory concentration (I 50) of S- an .
Cell Line IC50 BNS-DOX I 50 p-Value
MDA-MB231 1.6 ± 0.2 × 10−7 5 ± 0.2 × 10−7 0.001
4T1 2.8 ± 0.2 × 10−8 8.64 ± 0.8 × 10−8 0.0021
EMT6/AR10r 5.3 ± 0.67 × 10−6 29 ± 0.9 × 10−5 0.0045
MCF-7 1.5 ± 0.5 × 10−8 15 ± 0.9 × 10−7 0.001
Two-tailed p-value has been determined with unpaired t-test with Welch correction.
Results show that the inhibitory effect was exerted by BNS-DOX at a concentration always lower
(3–10 times lower) than free DOX. Since a main limitation of DOX is its cardiotoxicity, we performed
the same experiments on rat cardiomyocyte H9c2 cells, but results showed that BNS-DOX and DOX
did not display a substantial difference in inhibiting cell viability of these cells.
In order to assess whether the effects on the cell viability are related to inhibition of cell cycle
progression, a cell cycle analysis was performed after 72 h of culture in the presence and absence of
titrated amounts of DOX or BNS-DOX (Figure 3).
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Figure 3. Effects of DOX and BNS-DOX treatment on cell cycle. (A,B) MDA-MB231 and MCF-7 human 
breast cancer cell lines and (C,D) 4T1 and EMR6/AR10r mouse breast cancer cell lines (1.5 × 105) were 
treated or not with DOX and BNS-DOX for 72 h and the cell cycle was then assessed by flow 
cytometry. Graphs represented the % of the quantification of cell cycle phases from three independent 
experiments. 
The different cell lines showed distinct patterns of cell cycle distribution and BNS-DOX or DOX 
treatments showed variable effects, but the most consistent one was an increase of subG1 cells, 
induced to a higher extent by BNS-DOX compared to DOX. 
These data suggest that the inhibition of cell growth induced by DOX or BNS-DOX can be due 
to induction of apoptosis. To verify this possibility, cells cultured for 72 h in the presence and absence 
of titrated amounts of DOX or BNS-DOX were stained with annexin-V and analyzed by flow 
cytometry to detect dying cells (Figure 4). 
Fig re 3. Effects of an B S- treat ent on cell cycle. ( , ) - 231 an F-7 h an
breast cancer cell lines and ( , ) 4T1 and E 6/ 10r ouse breast cancer cell lines (1.5 × 105) ere
treated or not with DOX and BNS-DOX for 72 h and the cell cycle was then assessed by flow cytometry.
Graphs represented the % of the quantification of cell cycle phases from three independent experiments.
The different cell lines showed distinct patterns of cell cycle distribution and BNS-DOX or DOX
treatments showed variable effects, but the most consistent one was an increase of subG1 cells, induced
to a higher extent by BNS-DOX compared to DOX.
These data suggest that the inhibition of cell growth induced by DOX or BNS-DOX can be due to
induction of apoptosis. To verify this possibility, cells cultured for 72 h in the presence and absence of
titrated amounts of DOX or BNS-DOX were stained with annexin-V and analyzed by flow cytometry
to detect dying cells (Figure 4).
Results showed that treatment with DOX and BNS-DOX significantly increased the proportion of
Annexin-V-positive cells, and BNS-DOX was significantly more effective than DOX in all cell lines,
with patterns similar to those displayed by cell growth experiments.
To confirm the effect on cell apoptosis, we assessed caspase 3 activity on lysates of MDA-MB231,
4T1, and EMT6/AR10r cells cultured for 72 h in the presence and absence of titrated amounts of DOX
or BNS-DOX. Results showed that both DOX and BNS-DOX activated caspase3 in all cell lines, and
BNS-DOX was more effective than DOX (Figure 5).
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Figure 4. Effects of DOX and BNS-DOX treatment on cell death. Annexin-V positive cells were 
evaluated in (A,B) MDA-MB231 and MCF-7 human breast cancer cell lines and (C,D) 4T1 and 
EMR6/AR10r mouse breast cancer cell lines cultured for 72 h in the presence or absence of DOX or 
BNS-DOX. Results are expressed as % of positive cells from five independent experiments (* p < 0.05, 
** p < 0.01, versus the control; § p < 0.05, §§ p < 0.01, versus the same concentration). 
Results showed that treatment with DOX and BNS-DOX significantly increased the proportion 
of Annexin-V-positive cells, and BNS-DOX was significantly more effective than DOX in all cell lines, 
with patterns similar to those displayed by cell growth experiments. 
To confirm the effect on cell apoptosis, we assessed caspase 3 activity on lysates of MDA-MB231, 
4T1, and EMT6/AR10r cells cultured for 72 h in the presence and absence of titrated amounts of DOX 
or BNS-DOX. Results showed that both DOX and BNS-DOX activated caspase3 in all cell lines, and 
BNS-DOX was more effective than DOX (Figure 5). 
Figure 4. Effects of DOX and BNS-DOX treatment on cell death. Annexin-V positive cells were evaluated
in (A,B) MDA-MB231 and MCF-7 human breast cancer cell lines and (C,D) 4T1 and EMR6/AR10r
mouse breast cancer cell lines cultured for 72 h in the presence or absence of DOX or BNS-DOX. Results
are expressed as % of positive cells from five independent experiments (* p < 0.05, ** p < 0.01, versus
the control; § p < 0.05, §§ p < 0.01, versus the same concentration).
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Figure 5. Levels of caspase3 activity after DOX and BNS-DOX treatment. Caspase-3 activity was 
evaluated in (A) MDA-MB231 human breast cancer cell lines and (B,C) 4T1 and EMR6/AR10r mouse 
breast cancer cell lines cultured for 72 h in the presence or absence of DOX or BNS-DOX. Results are 
expressed as % calculated as follows: (result displayed by each treatment/the results displayed by 
untreated cells) from five independent experiments (* p < 0.05, ** p < 0.01, versus the control; § p < 0.05 
versus the same concentration). 
Since MCF-7 cells do not express caspase3 [14,15] we did not evaluate its activity in this cell line. 
To further compare the effect of the two drug formulations on mammary cancer cell growth, we 
performed a clonogenic assay. Cells were treated for 3 h in the presence and absence of titrated 
amounts of BNS-DOX or DOX, then, the drug was removed and cells were cultured for 10 days. This 
approach was used in order to determine if the nanoparticles, once they penetrated inside the tumor 
cell, were able to function as a reservoir and release the drug during an extended period of time. 
Colony count at the end of the culture showed that, also in this case, BNS-DOX was more effective 
than free DOX in inhibiting cell growth in all cell lines (Figure 6). 
Figure 5. Levels of caspase3 activity after D S-DOX treatment. C pase-3 activity was
evaluated in (A) MDA-MB231 human breast ce l lines and (B,C) 4T1 and EMR6/AR10r mouse
breast c ncer ll lines cult red for 72 h in th ce or absence of DOX or BNS-DOX. Results are
expressed as % calculated as follows: (result displayed by each treatment/the results displayed by
untreated cells) from five independent experiments (* p < 0.05, ** p < 0.01, versus the control; § p < 0.05
versus the same concentration).
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Since MCF-7 cells do not express caspase3 [14,15] we did not evaluate its activity in this cell
line. To further compare the effect of the two drug formulations on mammary cancer cell growth,
we performed a clonogenic assay. Cells were treated for 3 h in the presence and absence of titrated
amounts of BNS-DOX or DOX, then, the drug was removed and cells were cultured for 10 days. This
approach was used in order to determine if the nanoparticles, once they penetrated inside the tumor
cell, were able to function as a reservoir and release the drug during an extended period of time.
Colony count at the end of the culture showed that, also in this case, BNS-DOX was more effective
than free DOX in inhibiting cell growth in all cell lines (Figure 6).
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Figure 6. Effect of DOX and BNS-DOX on cell clonogenicity was tested by the colony forming assay. 
(A,B) MDA-MB231 and MCF-7 human breast cancer cell lines and (C,D) 4T1 and EMR6/AR10r mouse 
breast cancer cell lines were seeded in six-well plates and treated with each drug formulation at the 
indicated concentrations for 3 h. The medium was then changed and cells were cultured for an 
additional 10 days and subsequently fixed and stained with crystal violet. Graphs showed the % of 
clonogenicity inhibition (compared to controls) expressed as means ± SEM (n = 5). ** p < 0.01 
significantly different from the same concentration of DOX. 
To evaluate the cellular uptake of BNS-DOX in EMT6 cells confocal microscopy studies were 
carried out, exploiting the intrinsic red fluorescence of doxorubicin. BNS-DOX were easily 
internalized in cells, in agreement with our previous studies. Figure 7A reports the confocal 
microscopy images after 1 h and 3 h of incubation, showing the localization of BNS-DOX in cell 
cytoplasm around the nucleus. In contrast, a lower mean fluorescence intensity was observed for the 
cells treated with free DOX (Figure 7B). 
Fig re 6. ffect of a S- o cell clo oge icity as teste by t e colony for ing assay.
( , ) - - re st c cer cell li es ( , ) / r se
r st r cell lines were s eded in six-well plates and treated with each drug formulation at
the indicated o centrations for 3 h. The medium was then changed and cells were cultured f
i i l s a d subsequently fixed and stained with crystal violet. Graphs showed the %
of cl nogenicity inhibition (compared to controls) expressed as means ± SEM (n ). ** .
fi ff t fr t e sa e concentration of X.
l t t ll l t f - i ll f l i t i
i out, exploiting the intrinsic red fluorescence of doxorubicin. BNS-DOX were easily internalized
i cells, in agreement with our pr vious studies. Figure 7A reports the confocal microscopy images
afte 1 h and 3 h of incubation, showing the localization of BNS-DOX in cell cytoplasm around the
nucleus. In c ntrast, a lower mean fluorescence intensity was obs rv d for the cells treated with fre
DOX (Figure 7B).
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Figure 7. Cellular uptake studies. (A) BNS-DOX and DOX were incubated with EMT6 cells for 1 and 
3 h. Exploiting doxorubicin (Dox) fluorescence, the cells were fixed and analyzed with Leica SPE 
confocal microscopy using a 63× oil lens. Images are representative of three field per condition (n = 3). 
(B) Quantification of Dox fluorescence inside the cells from images in panel A (n  =  3). 
To compare the effect of DOX and BNS-DOX on breast cancer cell growth, we used the BALB-
neuT mice, which has a strong similarity with the human HER2-positive tumors. BALB-neuT females 
develop spontaneous breast tumors with 100% penetrance and a known kinetic: at 60 days from birth 
(9 week) they develop in situ carcinoma, at 120–150 days invasive tumors, and at 230 days cancerous 
extensive tumor masses involving all mammary glands [13,16–19]. The treatment with DOX and 
BNS-DOX began at 16–18 weeks from birth and mice were treated weekly with intravenous injections 
of DOX, BNS-DOX, empty nanoparticles (BNS), or PBS. The animal weight was of about 20 grams at 
time 0 (Figure 8B). At sacrifice, after 7 weeks from the beginning of the treatment, the tumor weights 
of mice treated with BNS-DOX were about 60% lower than those of mice treated with either PBS, 
DOX, or empty BNS (Figure 8A). 
Figure 7. Cellular uptake studies. (A) BNS-DOX and DOX were incubated with EMT6 cells for 1 and
3 h. Exploiting doxorubicin (Dox) fluorescence, the cells were fixed and analyzed with Leica SPE
confocal microscopy using a 63× oil lens. Images are representative of three field per condition (n = 3).
(B) Quantification of Dox fluorescence inside the cells from images in panel A (n = 3).
To compare the effect of DOX and BNS-DOX on breast cancer cell growth, we used the BALB-neuT
mice, which has a strong similarity with the human HER2-positive tumors. BALB-neuT females
develop spontaneous breast tumors with 100% penetrance and a known kinetic: at 60 days from birth
(9 week) they develop in situ carcinoma, at 120–150 days invasive tumors, and at 230 days cancerous
extensive tumor masses involving all mammary glands [13,16–19]. The treatment with DOX and
BNS-DOX began at 16–18 weeks from birth and mice were treated weekly with intravenous injections
of DOX, BNS-DOX, empty nanoparticles (BNS), or PBS. The animal weight was of about 20 grams at
time 0 (Figure 8B). At sacrifice, after 7 weeks from the beginning of the treatment, the tumor weights of
mice treated with BNS-DOX were about 60% lower than those of mice treated with either PBS, DOX, or
empty BNS (Figure 8A).
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Figure 8. Effect of DOX and BNS-DOX on tumor growth in vivo. Thirteen-week-old female wt or 
BALB-neuT mice were treated with i.v. injection of 2 mg/kg DOX, or BNS-DOX, or BNS or the same 
volume of PBS as a control for six weeks (once every week). Mice were sacrificed at the seventh week 
after the first injection. (A) The graph shows an average of the tumor mass weight, expressed as % 
compared to the control group. (B) Weight of the animals was evaluated every week from the day of 
the first injection, performed at T0 (when the tumor was palpable); each treatment involved 8 mice. 
(C) Immunofluorescence staining of cluster of differentiation 31 (CD31) and lymphatic vessel 
endothelial hyaluronan receptor 1 (LYVE-1) of tumour tissue sections from of Neu-T mice treated 
with DOX or BNS-DOX. The slides were stained with either pAb rabbit α-mouse CD31 or pAb rabbit 
α-mouse LYVE-1 plus a secondary antibody α-rabbit conjugated with Alexa Fluor®  488. 
Representative images of three independent experiments are shown (scale bar 100 µm)  
To assess the effect of treatments on tumor neoangiogenesis and lymphangiogenesis, we 
analyzed the expression of CD31 marking blood vessels and LYVE-1 marking lymphoid vessels by 
immunofluorescence in cryostat sections cut in OCT, which allows optimal retention of the structural 
micro-architecture. Results showed that tumors from mice treated with BNS-DOX and DOX 
displayed substantially fewer areas of active angiogenesis and lymphatic vasculature than the tumors 
from mice treated with DOX (Figure 8C). 
Since DOX is highly lipophilic and systemically distributes among all tissues, we compared the 
tissue biodistribution of doxorubicin in the tumors and several organs of BALB-neuT mice treated 
with either BNS-DOX or DOX at sacrifice by HLPC analysis. Analysis of the tumors showed that 
those from mice treated with BNS-DOX contained significantly more doxorubicin than those tumors 
from mice treated with DOX. Analysis of the organs showed that mice treated with BNS-DOX and 
DOX did not display substantial differences in the drug content of lungs, liver, kidneys, spleen, and 
brain, whereas the drug content of the heart was significantly lower (5 times lower) in BNS-DOX mice 
than in DOX mice (Figure 9A). 
Figure 8. Effect of X and B S- X on tu or growth in vivo. Thirteen- eek-old fe ale t or
B LB-neuT ice ere treated ith i.v. injection of 2 g/kg X, or B S- X, or B S or the sa e
volu e of PBS as a control for six eeks (once every eek). ice ere sacrificed at the seventh eek
after the first injection. ( ) he gra h sho s an average of the t or ass eight, ex resse as
co pared to the control group. ( ) eight of the ani als as evaluated every eek fro the day of
the first injection, performed at T0 (when the tumor was pal able); ach treatment i volved 8 mice. (C)
Immunofl orescence staining of cluster of differentiation 31 (CD31) and lymph tic vessel endoth lial
hyaluronan receptor 1 (LYVE-1) of tumour tissue sections from of Neu-T mice treated with DOX or
BNS- . The slides were sta n d with eith r pAb rabbit α-mouse CD31 or pAb rabbit α-mouse
LYVE-1 plus a secondary antibody α-rabbit conjugated with Alexa Fluor® 488. Representative images
of th e i dependent xperiments are shown (scale bar 100 µm), ** p < 0.01.
o as ess the effect of treatments on tumor neoangiogenesis and lymphangiogenesis, e
anal t i f CD31 marking bl od vessels and LYVE-1 marking lymphoid v s els
by i munofluorescence in cryostat sections cut in OCT, which allows opti al r t ti f t t t ral
icro-architecture. Results howed that tumors from mice treat d with BNS-DOX and DOX displayed
subst ntially fewer areas of activ angiogen sis and lymph tic vasculature than the tumors from ice
treated with DOX (Figure 8C).
Since is hig ly li o ilic a syste icall istri t s ll tiss s, co are the
tiss bio istri ti f i i i t t r se r l r s of B -ne ice treated
ith either BNS-DOX or DOX at sacrifice by HLPC analysis. Analysis of the tumors showed that those
from mice treat d wi h BNS-DOX contained significantly more doxorubicin than those umors from
mice treat d with DOX. Analysis of the rgans showed that mice treat d with BNS-DOX and DOX
did not isplay ubstantial differences in the drug content of lungs, liver, kidneys, spleen, and br in,
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whereas the drug content of the heart was significantly lower (5 times lower) in BNS-DOX mice than in
DOX mice (Figure 9A).Cancers 2020, 12, x 11 of 20 
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Figure 9. (A) Tissue biodistribution of DOX (expressed as µg/g tissue) after i.v. administration to
BALB-neuT and BALB mice of 2 mg/kg of DOX or BNS-DOX. (B) Histopathologic analysis of the
heart. Hematoxylin and eosin (H&E) stained were observed with 20×magnification (scale bar 100 µm).
Representative image of heart tissue from Neu-T mice treated with phosphate buffered saline (PBS),
DOX, or BNS-DOX. * p < 0.05.
Similar results were obtained by analyzing DOX distribution in control wild type BALB/c mice
(not developing mammary tumors) receiving the same BNS-DOX and DOX treatment as BALB/neuT
mice. In both BALB/c and BALB/neuT, treatment with BNS and DOX did not affect the weights of mice
and organs compared with those of untreated mice.
Since these data suggest that BNS-DOX might be less cardiotoxic than DOX, we analyzed tissue
sections stained with hematoxylin and eosin (H&E) staining obtained from the heart of mice treated
with either BNS-DOX or DOX. Microscopic analysis showed that BNS-DOX did not affect the integrity
and histology of the heart tissue, whereas DOX caused cardiotoxicity characterized by necrosis with
red blood cells extravasation and moderate eosinophil infiltration (Figure 9B).
3. Discussion
DOX is widely used as a chemotherapy agent for the treatment of breast cancer [1]. Its cytotoxic
and antiproliferative effects are exerted through several mechanisms, but the best known is in the
poisoning of topoisomerases II cleavage complexes [20,21], causing G1 and G2 cell cycle arrest and
induction of apoptosis. Other effects of DOX include its intercalation into DNA and the generation of
free radicals causing DNA damage and lipid peroxidation [22].
Lack of specificity with inability to discriminate between malignant and noncancerous cells are
the main causes of the side effects typical of standard DOX formulations, which limit doses and
effectiveness of the drug. Moreover, DOX (or its derivatives) use is limited by cardiac and kidney
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toxicity and frequent onset of drug resistance in numerous tumor cell types [1]. In breast cancer
cells, emergence of multidrug resistance (MDR) mainly involves upregulation of efflux transporters
that are either located in the plasma or the nuclear membrane, which decrease the intracellular drug
concentration [23].
Among them, the most extensively studied MDR transporters include P-glycoprotein
(P-gp/ABCB1), multidrug resistance protein-1 (MRP1/ABCC1), and breast cancer resistance protein
(BCRP, ABCG2) [24], all involved in drug inactivation and extrusion. Another possible feature of
cancer cells is ability to escape apoptosis, caused by alterations in the apoptosis pathways [25,26].
To overcome these problems, several delivery systems have been proposed as carriers for DOX, but
only liposomal DOX (Doxil®) achieved FDA approval in 1995 for treatment of Kaposi’s sarcoma [27].
Although Doxil® is able to decrease cardiotoxicity in metastatic breast cancer patients [28], this
formulation presents some limitations, such as fixed functionality, leakage of encapsulated agent, and
high cost of manufacturing [29]. Moreover, although Doxil® improves the pharmacokinetic properties
of DOX, it does not increase the pharmacological efficacy of DOX because of the insufficient cell uptake
of liposomes [30]. In this context, other types of DOX nanocarriers have been proposed [31], such as
poly(lactic-co-glycolic acid) (PLGA) nanoparticles [32], solid lipid nanoparticles [33] or nanosponges
with different structures [34–37].
Here, we investigated a new type of β-cyclodextrin nanosponges for the in vitro and in vivo
delivery of doxorubicin. The doxorubicin BNS formulation prepared for this study is capable of
incorporating a good amount of drug, forming a reservoir which allows the DOX release in a prolonged
manner. Notably, DOX incorporation in the polymer nanoparticles can be attributed to hydrophilic
and hydrophobic interactions. It is worth noting that nanosponges present multiple domains, i.e., the
hydrophobic β-CD cavities and the hydrophilic nanochannels in the polymer network. Moreover,
further electrostatic interactions between DOX amino groups and carboxylic groups of polymer matrix
may occur. This nanostructure feature can increase the effectiveness of the drug loading. The loading
capacity obtained in this study (16.4 w%) was in line with other nanosponge formulations previously
designed by our group [36,37]. This result is particularly promising taking into account also the DOX
incorporation in other kinds of nanocarriers reported in literature [33,38–41] Therefore, DOX-BNS was
further investigated both in vitro and in vivo.
In vitro studies showed the physical stability of BNS-DOX aqueous nanosuspension in plasma
without aggregation phenomena. The in vivo physical stability and safety of BNS-DOX after i.v.
administration are two key parameters to be taken into account for a nanoformulation [42]. As far as
concern the cytotoxicity, no toxic effects were observed with empty BNS.
Our in vitro experiments showed that BNS-DOX displays increased ability to decrease the growth
of both the ER/PR+ and the TNBC cell lines, and even of the DOX-resistant EMT6/AR10r cells,
compared to the free DOX. The similar efficacy between DOX and BNS-DOX, that was observed in
4T1 cells at higher drug concentrations, was probably linked to the relatively high sensitivity of this
cell line to DOX treatment. This observation was in agreement with the higher number of SubG1
cells found in 4T1 DOX-treated cells. The proportion of subG1 cells after DOX treatment depended
on the sensitivity of the different cell lines. Similar results were obtained in MCF-7 and MCF-7
DOX-resistant human breast cancer cells by De et al. 2014 [43]. Moreover, results obtained from the
clonogenic assay demonstrated that a short term exposure of cells to BNS-DOX is sufficient to elicit
subsequent inhibition of colony formation, possibly because of a rapid internalization of the drug into
the cancer cells, followed by sustained release and decreased extrusion by MDR mechanisms, such as
the energy-dependent Pg-p type efflux pumps which decrease the drug concentration in the cell and
its effectiveness. Clonogenic experiments showed that DOX inhibited cell proliferation at higher doses,
because it can enter inside the cells, thanks to its lipophilic characteristics, but it can easily extruded
by the cells by MDR mechanism. Carcinoma of colon, kidney, pancreas, and liver express high P-gp
levels, while lung, ovary, and breast carcinoma, melanoma, and lymphomas express low P-gp levels,
which often increase after chemotherapy causing acquired drug resistance [44]. Probably, BNS-DOX
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are internalized through endocytosis [45] and DOX is then slowly released in the cytoplasm far from
these efflux pumps, reducing drug elimination. Indeed, cell uptake studies by confocal microscopy
showed the internalization of BNS-DOX into the cells and their localization in the cytoplasm around
the cell nucleus. Therefore, BNS-DOX could act as a drug reservoir inside the cells, that slowly release
the drug.
The inhibitory effect on cell growth are mainly ascribable to induction of cell apoptosis, as indicated
by the increase of the sub-G1 cell population detected by cell cycle analysis, of the proportion of dying
cells stained by AnnexinV and of capsase3 activation.
The in vivo studies confirm the higher anticancer effect of BNS-DOX compared to DOX. Particularly
relevant was the choice of the murine BALB-neuT model, which recapitulates several features of
human tumors displaying mutations of the ERBB2 proto-oncogene coding for receptor tyrosine-protein
kinase erbB-2, also known as HER2 (from human epidermal growth factor receptor 2) or HER2/neu [46].
HER2 is a member of the epidermal growth factor receptors (EGFR) family that has a crucial role in
cell proliferation, apoptosis, adhesion, and cellular death; a mutation or an over expression of this
gene can lead to carcinogenesis [47]. Results show that BNS-DOX reduces by 60% the tumor growth
compared to DOX, at a 2 mg/kg dose that is 5-fold lower than the DOX therapeutic one (10 mg/kg).
Indeed, at this dose, the free DOX is almost ineffective. This outcome might be related to the enhanced
permeability and retention (EPR) effect. The irregular formation of blood and lymphatic vessels in
the tumor, favored the extravasation and entrapment of the nanoparticles in the target site. In line
with this possibility, our analysis of drug biodistribution detected higher levels of doxorubicin in the
tumors of the mice treated with BNS-DOX than in those treated with DOX.
Besides these effects, the increased therapeutic effect of BNS-DOX may be partly ascribed to
inhibition of tumor neoangiogenesis and lymphangiogenesis, detected by the immunohistological
analysis of cancer tissue sections, which would limit nutrients and oxygen available to the tumor,
and also tumor metastatic spread. Moreover, decreased lymphangiogenesis would favor entrapment
of BNS-DOX in the tumor. This behavior was already observed with paclitaxel loaded in BNS in
melanoma cell models [48].
Furthermore, the in vivo experiments did not detect severe toxic side effects of BNS-DOX, as a
matter of fact it did not affect the aspect of the fur, weight, consumption of food and water, and viability
of the animals. Interestingly, the drug biodistribution analysis showed drug levels in heart tissue of
mice treated with BNS-DOX are 5-fold lower than those detected in mice treated with DOX, which
may be relevant in decreasing the cardiotoxic side effects of DOX, being this effect the main limitation
of the drug. In line with this observation, histological analysis of heart tissue sections detected signs
of cardiac damage in the DOX-treated mice, but not in those treated with BNS-DOX. A further point
is that, in vitro too, BNS-DOX display less toxicity than DOX on cultures of rat cardiomyocytes. The
low level of heart accumulation might depend on the size (about 300 nm of diameter) and chemical
structure of our BNS, capillary filtration and modality of internalization into cells [49]. This capability
of doxorubicin loaded in nanosponges to reduce the cardiotoxicity was already observed with other
nanosponge formulations [37].
Taken together, all these results underline the promising features of BNS-DOX to improve the
therapeutic outcome of the drug.
4. Materials and Methods
4.1. Materials
The β-CDs were a kind gift from Roquette Italia (Cassano Spinola, Italy). All reagents were of
analytical grade. The laboratory reagents were from Sigma-Aldrich, unless otherwise specified. The
cell culture reagents were purchased from Gibco/Invitrogen (Life Technologies, Paisley, UK), unless
otherwise indicated.
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4.2. Preparation of Doxorubicin-Loaded Nanosponges
BNS were synthetized using β-cyclodextrins as building block and pyromellitic anhydride as
crosslinking agent in 1:4 molar ratio (CD/cross-linker). The synthesis was carried out according our
previous works [48,50].
A blank BNS aqueous nanosuspension (10 mg/mL) was prepared by homogenizing the BNS
coarse powder suspended in saline solution (NaCl 0.9% w/v) firstly with a high-shear homogenizer
(Ultra-Turrax, IKA, Konigswinter, Germany, 10 min, 24,000 rpm) and then with a high-pressure
homogenizer (EmulsiFlex C5, Avastin, Mannheim, Germany, 90 min, 500 bar) to further reduce the
BNS size.
Then, doxorubicin was added to the blank BNS nanosuspension to obtain doxorubicin loaded
BNS (BNS-DOX) at a concentration of 2 mg/mL. The sample was incubated under stirring for 24 h at
room temperature in the dark, to promote the loading. A dialysis step was performed to eliminate the
unloaded doxorubicin.
4.3. Characterization of Doxorubicin-Loaded Nanosponges
BNS and BNS-DOX samples were in vitro characterized by determining their average diameter,
polidispersity index, and zeta potential with dynamic light scattering (90 Plus particle sizer, Brookhaven
Instruments Corporation, Holtsville, NY, USA). The samples were diluted with water (1:30 v/v)
immediately prior the measurements, carried out at a fixed angle of 90◦ and at a temperature of 25 ◦C.
Transmission electron microscopy (TEM) analysis was performed using a Philips CM 10 transmission
electron microscope to observe the morphology of BNS-DOX. The BNS nanosuspensions were sprayed
on Formvar coated copper grid and air-dried before observation.
A weighted amount of freeze-dried BNS-DOX was dispersed in 5 mL of water and sonicated for
15 min. The sample was then centrifuged (10 min, 15,000 rpm) and after the supernatant was analyzed
by High Performance Liquid Cromatography (HPLC), to determine the DOX concentration in the BNS.
The loading capacity of BNS-DOX was calculated according to: Loading capacity (%) = [amount
of DOX/weight of BNS-DOX] × 100. The encapsulation efficiency of BNS-DOX was determined using
the formula: Encapsulation efficiency (%) = [amount of DOX loaded/total amount of DOX] × 100.
The physical stability of BNS-DOX stored at 4 ◦C was assessed up to 1 month, by checking the
physicochemical parameters over time.
4.4. In Vitro Release Studies
The in vitro release kinetics of DOX from BNS-DOX was evaluated with a multi-compartment
rotating cell, using a cellulose membrane (Spectrapore, cut-off = 12,000 Da) to separate the donor
from the receiving compartment. The in vitro drug release studies were performed at two different
pH values (5.5 and 7.4). Samples of receiving phase (phosphate buffered saline, PBS at pH 5.5 or 7.4)
were withdrawn at fixed times and analyzed by HPLC to quantify the amount of drug released from
BNS-DOX over time. DOX was detected using a fluorescence detector at excitation and emission
wavelengths of 480 and 560 nm, respectively.
4.5. Stability and In Vitro Release Studies in Plasma
The stability of BNS-DOX was investigated in plasma, determining their size and DOX
concentration over time after BNS-DOX incubation in plasma at 37 ◦C for 24 h. The in vitro release
kinetics of DOX from BNS-DOX in plasma was also studied. For this purpose 50 microliters of
BNS-DOX were incubated at 37 ◦C with rat plasma diluted with PBS at pH = 7.4 (1:3 v/v). At fixed time
200 microliters of the sample were withdrawn, centrifuged using a centrifugal filter device (Amicon®
Ultra, 20,000 rpm, 10 min) and then the filtrate was analyzed by HPLC to quantify the amount of DOX
released from BNS-DOX over time.
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4.6. Cell Culture Conditions
Cancer cell lines were obtained from the American Type Culture Collection (ATCC; Manassas,
VA, USA). MDA-MB231, MCF-7, H9c2 were grown in culture dishes as a monolayer in Dulbecco’s
Modified Eagle (DMEM) medium (Invitrogen, Burlington, ON, Canada), 4T1 in RPMI 1640, and
EMT6/AR10r DOX resistant in Minimum Essential Medium (MEM), all supplemented with 10%
penicillin-streptomycin (Invitrogen) and 10% fetal calf serum (Invitrogen), in a humidified atmosphere
with 5% CO2. In the case of EMT6/AR10r DOX resistant cell lines, 1 µg/mL of DOX was added in the
culture medium once a week.
4.7. Cell Proliferation
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide; Sigma-Aldrich, St. Louis,
MA, USA) analysis was performed in 96-well plates. Briefly, 1000–2000 cells/well were seeded in
100 µL of complete medium and the day after they were treated with DOX or BNS-DOX (10−5–10−9 M)
for 72 h. Subsequently, cells were supplemented with 5 mg/mL thiazolyl blue tetrazolium bromide
(M2128; Sigma-Aldrich) for 2 h. Thereafter, the medium was removed and cells were lysed with 100 µL
of DMSO. Absorbance was recorded at 570 nm by a 96-well-plate reader (PerkinElmer, Waltham, MA,
USA). Controls were normalized to 100%, and the readings from treated cells were expressed as %
of viability inhibition. Eight replicates were used to determine each data point, and five different
experiments were performed.
4.8. Colony-Forming Assay
Cells (800/well) were seeded into six well plates and treated with the compounds. The medium
was changed after 3 h and cells were cultured for additional 10 days. Subsequently, cells were fixed and
stained with a solution of 80% crystal violet and 20% methanol. Colonies were then photographed and
counted with a Gel Doc equipment (Bio-Rad Laboratories, Hercules, CA, USA). Then, cells were washed
and 30% acetic acid were added to induce a complete dissolution of the crystal violet. Absorbance
was recorded at 595 nm by a 96-well-plate ELISA reader. Controls were normalized to 100%, and the
readings from treated cells were expressed as % of viability inhibition. Five different experiments
were performed.
4.9. Cell Cycle Analysis
Treated and untreated cells were harvested 72 h after the treatment with DOX or BNS-DOX at
different concentrations. Cells were washed with 1× PBS, fixed in 70% cold ethanol, resuspended in a
buffer containing 0.02 mg/mL RNase A (Sigma-Aldrich), 0.05 mg/mL propidium iodide (Sigma-Aldrich),
0.2% v/v Nonidet P-40 (Sigma-Aldrich), 0.1% w/v sodium citrate (Sigma-Aldrich), and analyzed by a
FACS Calibur cytometer (Becton Dickinson, Franklin Lakes, NJ, USA).
4.10. Cell Death
Treated and untreated cells were harvested 72 h after the treatment with different concentration
of DOX or BNS-DOX, washed with 1× PBS, and subsequently resuspended in Annexin-V binding
buffer (Life Technologies, Carlsbad, CA, USA) supplemented with 1:100 APC-conjugated Annexin-V
(Immunotools, Friesoythe, Germany). Cells were analyzed by a FACS Calibur cytometer (Becton
Dickinson, Franklin Lakes, NJ, USA). The analysis of apoptosis was performed by measuring the
caspase 3 activity in cell lysates using a fluorimetric assay (BioVision, Milpitas, CA, USA) following
the manufacture’ instructions.
4.11. Cell Uptake Studies
EMT6 cells (4 × 104 cells per well) were seeded on Corning® cover glasses (Sigma-Aldrich) in a
24-well plate. The day after, the cells were incubated with BNS-DOX and DOX (30 µM) for 1 and 3 h.
Cancers 2020, 12, 162 15 of 19
Then, the cells were washed with PBS, fixed with 4% paraformaldehyde at room temperature for 15
min, and stained with 4′,6-diamidine-2-phenylindole (DAPI). Finally, coverslips were mounted and
the image acquisition was performed with a Leica SPE Confocal microscope (Leica, Wetzlar, Germany),
with 63X oil-immersion objective. The mean fluorescence intensity of Dox was quantified by ImageJ
software (ImageJ, U.S. National Institutes of Health, Bethesda, MD, USA).
4.12. In Vivo Experiments
Transgenic (BALB-neuT) female mice, which over-express the rat HER2 (neu) oncogene under
the mouse mammary tumor virus (MMTV) promoter [51] and wild type mice (BALB), 16–18 weeks
old, were used. BALB-neuT and BALB mice were treated every week with intravenous injections (i.v.)
of 2 mg/kg of DOX, BNS-DOX, empty nanoparticles (BNS), or PBS as control. Mice were bred under
pathogen-free conditions in the animal facility of the Università del Piemonte Orientale, and treated
in accordance with the Bioethics Committee of University of Turin, protocol NO. 479 of 1 November
2016. Body weight of the animals was monitored over time. Mice were sacrificed 7 weeks after the
beginning of treatment and tumors were harvested and weighed. Immediately after dissection, tumor
samples were embedded in OCT compound, snap-frozen and stored at −80 ◦C until use.
The biodistribution of DOX and BNS-DOXwas evaluated after the mice sacrifice. The different
tissues (liver, spleen, brain, heart, lungs, and kidneys) were collected, washed with saline solution,
weighed, and frozen at −80 ◦C until analysis. Tissue extracts were prepared by adding 200 µL of
methanol and 400 µL of TRIS buffer (1 M, pH 8.5) to the tissue and then homogenizing the mixtures.
The tissue homogenates were kept in ice for 15 min before adding 1.4 mL of acetonitrile. Then,
the samples were vortex and centrifuged for 5 min at 15,000 rpm to separate the precipitated proteins.
After centrifugation clear supernatants (100 µL) were analyzed by HPLC analysis, to quantify the
amount of DOX in the tissue extracts.
4.13. Immunofluorescence
Tumor tissues were cut with a cryostat (thickness 5–6 µm) and treated with 4% paraformaldehyde
(Sigma-Aldrich) diluted in PBS for 5 min at room temperature to fix the sample on the glass slides.
The samples were then blocked with 5% normal goat serum (NGS) in PBS for 1 h, in order to block
aspecific sites to which the primary antibody could bind. To detect CD31 and LYVE-1 expression,
slides were incubated with the primary rabbit antibody anti-CD31 or anti-LYVE-1 (dilution 1:100
and 1:200, respectively; Abcam, Cambridge, UK) overnight at 4 ◦C. The secondary antibody used
was an anti-rabbit Ig Alexa fluor 488-conjugated (Invitrogen), diluted 1: 400. Then the sections were
stained with 0.5 mg/mL of the fluorescent dye 4,6-diamidino-2-phenylindole-dihydrochloride (DAPI,
Sigma-Aldrich) for 5 min, to stain the cell nuclei, and then mounted using Prolong anti-fade mounting
medium (Light AntiFADE Kit, Molecular Probes Invitrogen). The sections were then observed by a
fluorescence inverted Axiovert 40 CFL microscope (Carl Zeiss, Oberkochen, Germany), photographed
with a Retiga 200R digital camera (QImaging, Surrey, BC, Canada), and analyzed with the Image Pro
Plus Software for micro-imaging 5.0 (Media Cybernetics, version 5.0, Bethesda, MD, USA).
4.14. Histopathological Examination
Transverse midsections of hearts were fixed in 10% buffered formalin, embedded in paraffin, cut
into 5 µm sections, and processed for hematoxylin and eosin (H&E) staining to determine the level of
inflammation. Stained sections were analyzed by light microscope (DM 2500 Leica) connected to a
digital camera (DFC 320, Leica, Milan, Italy). The sections were morphologically examined to evaluate
the inflammatory infiltration levels.
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4.15. Data Analysis
Data are shown as mean ± SEM. The statistical analyses were performed with GraphPad Prism 3.0
software (San Diego, CA, USA) using the one-way ANOVA and Dunnett test. IC50 was investigated
using the two tailed unpaired t-test with Welch correction. The significance cut-off was p below 0.05.
5. Conclusions
BNS-DOX proved to be a promising effective nanoformulation in the treatment of breast cancer.
The increased effectiveness, compared to DOX, may be due to a higher accumulation into the tumor
mass and the neoplastic cells. Moreover, the reduced biodistribution in the heart tissue suggests a
reduced cardiotoxicity of BNS-DOX. Therefore, this nanoformulation, which increases DOX efficacy
and decreases its severe side effects, might be an attractive tool for improving the clinical management
of breast cancer.
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Abbreviations
DOX doxorubicin
BNS-DOX β-Cyclodextrins Nanosponges containing doxorubicin
EPR enhanced permeability and retention effect
CD cyclodextrin
BNS β-cyclodextrin nanosponges
TBNC Triple negative cell-lines
P-gp P-glycoprotein
PLGA poly (lactic-co-glycolic acid)
EGFR epidermal growth factor receptors
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide
MMTV mouse mammary tumor virus
NGS normal goat serum
H&E hematoxylin and eosin
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